Aptar today announced that Sarah Glickman, an accomplished leader with more than 30 years of global financial and operational experience, has joined its Board of Directors.
“We are pleased to welcome Sarah Glickman to our Board of Directors. Sarah’s extensive knowledge of all aspects of corporate finance coupled with her global operational experience, including in the pharmaceutical industry for companies like Novartis and Bristol-Myers Squibb, makes her an important addition to Aptar’s Board of Directors,” said Stephan B. Tanda, Aptar President and CEO.
Sarah currently serves as the Chief Financial Officer and Principal Accounting Officer for Criteo S.A., a global commerce media company. Prior to joining Criteo, Sarah was the Acting Chief Financial Officer at XPO, Inc. She also held global executive roles at Novartis and Honeywell International and started her career at PricewaterhouseCoopers. Since 2021, Sarah has served on the Board of Directors and is Chair of the Audit Committee for 2seventy bio, Inc., a biotech company (previously part of bluebird bio, Inc.).
Candace Matthews, Chairperson of Aptar’s Board of Directors, stated, “We are excited to welcome Sarah to Aptar’s Board of Directors. Her strong operational and financial leadership roles in large and complex global companies, such as Honeywell International, will benefit Aptar and its shareholders. Sarah’s appointment also underscores Aptar’s commitment to a demographically and culturally diverse board; with her appointment five out of the ten directors are women.”
On her appointment, Sarah Glickman said, “I am thrilled to join Aptar’s Board of Directors. I look forward to leveraging my experience and perspective to help the company continue to grow and increase shareholder value while staying true to Aptar’s purpose of transforming ideas into solutions that improve everyday life.”
Glickman is a U.S. CPA and a U.K. Fellow Chartered Accountant with a degree in economics from the University of York, England.
Learn more about Aptar’s Board of Directors here.